MJA
MJA InSight
MJA Careers
Letters

An audit of dabigatran etexilate prescribing in Victoria

Sueh-li A Lim and Ellen Maxwell
Med J Aust 2013; 198 (6): 314-315.
doi:
10.5694/mja12.10942

To the Editor: In 2009, the RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) trial compared dabigatran etexilate with warfarin for prevention of stroke and systemic embolism in 18 113 patients with non-valvular atrial fibrillation (AF) and at least one additional risk factor

Sueh-li A Lim, Haematology Registrar1,2
Ellen Maxwell, Director of Haematology2
1 The Alfred Hospital, Melbourne, VIC.
2 Melbourne Pathology, Melbourne, VIC.
Article References: 
Reference Text: 
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
Reference Order: 
1
PubMed ID: 
19717844
Reference Text: 
Department of Health and Ageing. Important new medicines listed on the PBS. http://www.health. gov.au/internet/ministers/publishing.nsf/Content/mr-yr11-nr-nr196.htm (accessed Sep 2011).
Reference Order: 
2
PubMed ID: 
Reference Text: 
Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-1286.
Reference Order: 
3
PubMed ID: 
21788545
Reference Text: 
Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-866.
Reference Order: 
4
PubMed ID: 
22375994
Reference Text: 
Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
Reference Order: 
5
PubMed ID: 
20801496

The full contents of this page are only available to subscribers.